Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Refractory anemia with excess blasts in transformation (RAEB-T) is characterized by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood. The peripheral blood blast count ranges from 20% to 30%. RAEB-T used to be a subcategory of myelodysplastic syndromes in the past. Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes. The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%. The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments. Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome). A minority of cases are part of RAEB-2.
Biomarker and diagnostic research for refractory anemia with excess blasts in transformation has been reported in the published literature.
No clinical trials have been registered for refractory anemia with excess blasts in transformation.
2 publications have been identified in PubMed for refractory anemia with excess blasts in transformation. Research spans Diagnostic / Biomarker (50%) and Review / Meta-Analysis (50%).
Liu L (2025). [PMID: 40646469](https://pubmed.ncbi.nlm.nih.gov/40646469/). *BMC Cancer*. [Diagnostic / Biomarker]
Lapadat ME (2025). [PMID: 41283234](https://pubmed.ncbi.nlm.nih.gov/41283234/). *Hematol Rep*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:25 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center